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Abstract: It is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, lung cancer 
and malignant mesothelioma (MM) not only in people who have handled asbestos in the work environment, but also in 
residents living near factories that handle asbestos. These facts have been an enormous medical and social problem in Japan 
since the summer of 2005. We focused on the immunological effects of asbestos and silica on the human immune system. 
In this brief review, we present immunological changes in patients with MM and outline their experimental detection. For 
example, there is over-expression of bcl-2 in CD4+ peripheral T-cells, high plasma concentrations of interleukin (IL)-10 
and transforming growth factor (TGF)-ß, and multiple over-representation of T cell receptor (TcR)-Vß in peripheral 
CD3+ T-cells found in MM patients. We also detail an experimental long-term exposure T-cell model. Analysis of the 
immunological effects of asbestos may help our understanding of the biological effects of asbestos.
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Introduction
It is common knowledge that asbestos exposure causes asbestos-related diseases such as asbestosis, 
lung cancer and malignant mesothelioma (MM) not only in people who have handled asbestos in the 
work environment, but also in residents living near factories that handle asbestos. These facts have been 
an enormous medical and social problem in Japan since the summer of 2005 (Kanazawa et al. 2006; 
Murayama et al. 2006; Nakano, 2006). Several patients with MM living in Amagasaki, Hyogo prefec-
ture, Japan have featured in news reports. These patients resided 1 km from an asbestos factory and had 
no identiﬁ  able occupational exposure to asbestos. Given that MM is an incurable disease and progno-
sis is not promising (Vogelzang and Pass, 2006; Zucali and Giaccone, 2006; Tsiouris and Walesby, 
2007), and considering the absence of effective government legislation concerning the usage of asbes-
tos, people in Japan have become concerned about social and medical issues related to asbestos.
Asbestos is categorized as a silicate (mineralogical complexes containing metals, such as iron and 
magnesium) and includes forms such as chrysotile, crocidolite, and amosite. Patients exposed to asbes-
tos develop pulmonary ﬁ  brosis known as asbestosis, mesothelial plaque and malignant diseases such 
as lung cancer and MM (Niklinski et al. 2004; Becklake et al. 2007; O’Reilly et al. 2007). The mecha-
nisms of asbestos-induced carcinogenesis are thought to produce an accumulation of DNA damage due 
to asbestos-induced production of reactive oxygen/nitrogen species (ROS/RNS) and an escape from 
the asbestos-induced activation of the mitochondrial apoptotic pathway (Shukla et al. 2003; Upadhyay 
and Kamp, 2003). In addition, we believe that some of these malignancies may be caused by a decline 
in tumor immunity owing to exposure of immunocompetent cells to asbestos.
Silica is known as one of the strongest environmental substances that cause autoimmunity dysfunction 
(Hess, 2002; Cooper and Parks, 2004). Silicosis patients often develop immunological complications 
such as rheumatic arthritis (known as Caplan syndrome (Caplan, 1953)), systemic sclerosis (SSc), and 
systemic lupus erythematoses (SLE). The effects of silica on autoimmunity have also been recognized 12
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following the discovery that patients who receive 
plastic surgery with implants containing silicone 
([SiO2-O-]n) show frequent complications involv-
ing autoimmune disorders (Shons and Schubert, 
1992; Hirmand et al. 1993). These ﬁ  ndings clearly 
indicate that crystalline silica causes dysregulation 
and/or disturbance of the human immune system, 
particularly autoimmunity.
The overall evidence suggests that asbestos may 
inﬂ  uence human immunocompetent cells and that 
such alterations may affect the occurrence and 
progression of asbestos-related malignant diseases. 
Thus, we have focused on the immunological 
effects of asbestos. Among the many types of 
asbestos, chrysotile has mainly been used in our 
experiments. It is known that magnesium, the main 
compartment of chrysotile as silicate, usually dis-
sociates from the chrysotile core (SiO2) in the 
human body after inhalation, and chrysotile is 
known to induce malignant transformation. How-
ever, its carcinogenic capacity is lower than that 
of other forms of iron-containing asbestos such as 
crocidolite and amosite (Harington, 1991).
In this article, we present immunological 
changes in MM patients with our experimental 
model. These changes may have resulted from the 
immunological effects of asbestos on human 
immunocompetent cells, and may offer some sug-
gestions for the immunological prevention of the 
occurrence and progression of asbestos-induced 
malignant diseases.
bcl-2 expression of peripheral 
CD4+ T cells in MM patients
As shown in the upper panel of Figure 1-A, periph-
eral CD4+ T cells from MM patients showed a 
signiﬁ  cantly higher expression of bcl-2 compared 
to that of healthy volunteers (Miura et al. 2006). 
This may suggest that the over-expression of bcl-2 
in peripheral CD4+ T cells is one of the markers 
for the occurrence of MM, although it should be 
determined whether many cancer-bearing patients 
respond in a similar manner. The experimental 
background of this ﬁ  nding is as follows.
Experiments that exposed a high dose of chrys-
otile to peripheral fresh T cells or T cell-derived 
cell lines for a short time revealed that a human 
T-cell leukemia virus type-1 (HTLV-1)-immortal-
ized human polyclonal T-cell line, MT-2, under-
went apoptosis with ROS production via activation 
of the mitochondrial apoptotic pathway with the 
phosphorylation of p38 mitogen-activated protein 
kinase (MAPK) and c-Jun N-terminal kinase (JNK) 
signaling molecules. In addition, we observed a 
shift of the Bax-dominant Bax/Bcl-2 balance, the 
release of cytochrome-c from mitochondria into 
the cytosol, and the activation of caspases 9 and 3 
upon short-term, high-level exposure to chrysotile 
(Hyodoh et al. 2005). However, we thought that 
an in vitro experimental model of chronic exposure 
was necessary in order to analyze the immunobio-
logical effects of silicates during long-term expo-
sure and to transfer these experimental ﬁ  ndings to 
clinical analyses.
Thus, we established a chrysotile-induced apop-
tosis-resistant subline of MT-2 (MT-2Rst), and 
characterized the cell biological differences 
between the original MT-2 cell line (MT-2Org) and 
MT-2Rst. MT-2Rst cells were characterized by (i) 
an enhanced expression of bcl-2 as shown in the 
lower panel of Figure 1-A, restoring apoptosis 
sensitivity with the decrease in bcl-2 expression 
level by siRNA, (ii) excessive interleukin (IL)-10 
secretion and expression, and (iii) the activation 
of signal transducers and activators of transcription 
(STAT) 3 inhibited by 4-amino-5-(4-chlorophenyl)-
7-(t-butyl) pyrazolol [3,4-d] pyrimidine (PP2), a 
speciﬁ  c inhibitor of Src family kinases. These ﬁ  nd-
ings suggest that contact between cells and asbes-
tos may affect the human immune system and 
trigger a cascade of biological events, such as the 
activation of Src family kinases, enhancement of 
IL-10 expression, STAT3 activation, and Bcl-2 
over-expression as previously reported (Miura 
et al. 2006).
Another interesting ﬁ  nding was obtained from 
analyses using bcl-2 expression in peripheral 
CD4+ T cells. We performed factor analysis using 
various clinical parameters and the bcl-2 relative 
expression ratio (bcl-2 RER) obtained by real-time 
RT-PCR from MM patients. Our results revealed 
that bcl-2 RER, a past history of asbestos exposure, 
peripheral platelet counts, and serum CRP values 
formed one factor, and these parameters exhibited 
higher, present, lower count, and lower values, 
respectively, as shown in Table 1. Platelet-derived 
growth factor (PDGF) is one of the widely known 
MM-related growth factors and it functions as the 
autocrine/paracrine proliferation-promoting factor 
for mesothelioma cancer cells (Langerak et al. 
1996, Klominek et al. 1998). Although higher 
serum levels of PDGF in MM patients are thought 
to be produced from mesothelioma cells and bcl-2 13
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Figure 1. Comparison of bcl-2 relative expression ratio vs. gapdh plasma concentrations in anti-inﬂ  ammatory cytokines in MM 
patients and healthy volunteers (HV), and bcl-2 expression and secretion of these cytokines from experimental low-dose and 
long-term exposed T-cell models to asbestos (MT-2Org and MT-2Rst, see text for details).
Panel A shows the relative expression ratio of bcl-2 in peripheral blood CD4+ cells (upper panel) from MM patients and HV, or in cultured 
MT-2Org and MT-2Rst cells (lower panel). Panels B and C show the plasma concentrations of IL-10 (B) and TGF-ß (C) from MM patients 
and HV (upper panels), or the concentrations in culture supernatants of IL-10 (B) and TGF-ß (C) from MT-2Org and MT-2Rst cells (lower 
panels).
Peripheral blood mononuclear cells (PBMCs) were isolated from the heparinized blood of healthy donors and MM patients using a Ficoll-
Hypaque density gradient (Separate-L
®, Muto Pure Chemicals Co. Ltd., Tokyo, Japan). For the isolation of CD4+ T cells, PBMCs were 
further separated using Magnetic Cell Separation (MACS) CD4 MicroBeads (Miltenyi Biotech, Bergisch Gladbach, Germany) according to 
the manufacturer’s instructions. The enriched cells were 90% pure as determined by ﬂ  ow cytometry. Specimens were taken from healthy 
volunteers and patients from whom informed consent had been obtained. The Institutional Ethics Committee of Kawasaki Medical School, 
Hyogo College of Medicine, and Okayama Rosai Hospital approved the project. A ﬂ  uorescence thermocycler (Mx3000P
® QPCR System, 
Stratagene Corporation, La Jolla, CA) was used for real-time RT-PCR experiments by following the instructions of the manufacturer. The 
ﬂ  uorescence-labeled ampliﬁ  cation product is measured continuously with this technique. Total RNA obtained from CD4+ T cells isolated 
from peripheral CD4+ T cells was extracted using an RNA Bee kit (Tel-Test, Inc., Friendswood, Texas), and 5 µg of RNA was reverse-
transcribed with standard methods using a RevertAid™ H Minus First Strand cDNA Synthesis Kit (Fermentas International Inc., Ontario, 
Canada). An amount of cDNA equivalent to 50 ng of RNA served as the template for PCR in a volume of 20 µl (each primer and SYBER 
Premix Ex Taq, TaKaRa). The primers for bcl-2 and gapdh were added to the same reaction tube at the optimal concentration for each 
primer set and PCR was performed. Primers were as follows: bcl-2; 5'-TGATGTGAGTCTGGGCTGAG-3' (Forward: Fw) and 5'-
GAACGCTTTGTCCAGAGGAG-3' (Reverse: Rv), Bax; 5'-AGTAACATGGAGCTGCAGAGG-3' (Fw) and 5'-ATGGTTCTGATCAGTTCCGG-
3' (Rv), gapdh; 5'-GAGTCAACGGATTTGGTCGT-3' (Fw) and 5'-TTGATTTTGGAGGGATCTCG-3' (Rv).
The relative expression of various target genes such as bcl-2 was calculated as follows when real-time RT-PCR was performed: [A: number 
of PCR cycles required to reach a certain intensity of ﬂ  uorescence for the gapdh product. B: number of PCR cycles required to reach the 
same ﬂ  uorescent intensity for the target gene product (bcl-2) derived from the same sample.] The relative level of the target gene is expressed 
as 1/2[B-A], with gapdh expression being 1.0. PCR products were conﬁ  rmed to be successfully ampliﬁ  ed by standard agarose gel electro-
phoresis and staining with ethidium bromide. Comparisons of the results for relative gene expression and proliferation assayed by real-time 
RT-PCR were analyzed using the Mann-Whitney U-test.
Cytokines in plasma from MM patients and HV and culture supernatant were measured using an ELISA kit (Quantikine
® Human TGF-ß1 
(or IL-10) Immunoassay; R&D Systems) and the Cytometric Bead Array of Human Th1/Th2 cytokine kit II (CBA, BD Bioscience, San Jose, 
CA, U.S.A.), and measurements were made using FACSCalibur ﬂ  ow-cytometry (BD Bioscience) according to the manufacturer’s 
instructions.
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RER is a marker of T cells chronically exposed to 
asbestos, these may be unknown biological 
mechanisms between immunocompetent cells with 
chronic exposure to asbestos and peripheral platelet 
counts via PDGF.
IL-10 and TGF-ß concentrations 
in MM patients and the experimental 
model
As shown in the upper panels of Figures 1-B and 
1-C, plasma concentrations of IL-10 and transform-
ing growth factor (TGF)-ß were significantly 
higher in MM patients than in healthy volunteers. 
TGF-ß is known as one of the mesothelioma cell-
producing cytokines (Gerwin et al. 1987; Maeda 
et al. 1994). However, the above-mentioned MT-
2Rst cells, representing the outcome of the exper-
imental low-dose and long-term asbestos-exposure 
T-cell model, showed signiﬁ  cantly higher secretion 
of TGF-ß than MT-2Org cells (lower panel 
of Fig. 1-C). As we mentioned previously, the 
IL-10 concentration in culture supernatants of 
MT-2Rst was higher than that of MT-2Org (lower 
panel of Fig. 1-B). Thus, the source of the elevated 
TGF-ß and IL-10 concentrations in MM patients 
is not only tumor cells, but also immunocompetent 
cells.
It is interesting to note that IL-10 and TGF-ß 
are the important soluble factors necessary for the 
function of CD4+25+FoxP3+ regulatory T cells 
(Treg), even though cell-cell contact is the main 
route for the manifestation of Treg function (Wahl 
et al. 2004; Romagnasi, 2006). If circulating Treg 
and tumor-inﬁ  ltrated Treg have enhanced function 
as a result of these elevated concentrations of IL-10 
and TGF-ß, further aggressive progression of 
asbestos-induced cancer cells may have occurred. 
It may be important to analyze the Treg function 
using the experimental model that we have 
developed.
T-cell receptor (TcR) Vß expression
We reported previously that asbestos may act on 
peripheral T cells as a superantigen (Aikoh et al. 
1998; Ueki, 2001). The effects of a superantigen 
such as staphylococcal enterotoxin B (SEB) may 
modify TcRVß on peripheral T cells to enhance 
multiple, but not clonal, TcRVß expression 
(Schubert, 2001; Li et al. 1999). As shown in 
Figure 2, various TcRVßs were over-expressed in 
MM and asbestosis patients. TcRVßs from most 
patients showed a higher expression, exceeding 
the average plus 2SD (standard deviation) limit. 
In addition, several TcRVßs such as Vß 1, 4 and 9 
among the 24 kinds of TcRVß were strongly over-
expressed in many patients. This phenomenon was 
also observed from the comparison of TcRVß 
expression in MT-2Org and MT-2Rst cell lines. As 
a result, MT-2Rst cells over-expressed various 
TcRVßs. Although TcRVß-overexpressing MT-
2Org cells underwent apoptosis due to their ﬁ  rst 
contact with chrysotile, MT-2Rst cells showed no 
signiﬁ  cant changes when they again came in con-
tact with chrysotile (Nishimura et al. 2006). These 
ﬁ  ndings may suggest that the over-expression of 
various TcRVßs may be the result of contact 
between cells and chrysotile, an asbestos ﬁ  ber, 
during the acquisition of resistance to CB-induced 
apoptosis caused by a long-term and low-dose 
exposure to CB (Nishimura et al. 2006).
The multiple over-expression of TcRVß in 
CD3+ peripheral T cells derived from asbestos-
exposed patients may be one of the candidates to 
detect previous asbestos exposure. Although these 
Table 1. Factor analysis of clinical parameters in 
mesothelioma patients with relative bcl-2 expression in 
peripheral CD4+ T cells.
Parameter Value (a value of more 
than ± 0.4 is thought to 
contribute to the 
formation of this factor)
bcl-2 relative expression 
ratio in peripheral 
CD4+ T cells
0.59009
Histology (numbered)
epithelial type = 1
mixed type = 2
sarcomatous type = 3
−0.14234
Past asbestos exposure 
(numbered)
existence = 1
unknown = 2
none = 3
0.55496
White Blood Cell count  0.22054
Platelet count −0.76064
Concentration of serum 
creatinine
0.21269
Concentration of serum 
CRP
−0.79789
Contribution rate 19.18%15
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data were obtained from a limited number of 
patients, it is worth continuing these analyses using 
samples from many patients in an effort to explore 
the biological mechanisms involved in these 
ﬁ  ndings.
Conclusion
A summarized schematic presentation of various 
aspects of this investigation is shown in Figure 3. 
This schema only shows the experimental and 
clinical ﬁ  ndings related to asbestos exposure of 
T cells. We have been investigating the effects of 
asbestos on the function of natural killer (NK) cells 
from cellular and molecular viewpoints. TGF-ß is 
similar to PDGF in that it is also known as a 
mesothelioma-producing growth factor (Gerwin 
et al. 1987; Maeda et al. 1994; Langerak et al. 
1996; Klominek et al. 1998). Thus, the effects of 
TGF-ß1 on asbestos-exposed MT-2Rst cells are 
being investigated and compared with MT-2Rst 
and MT-2Org cells that have not been exposed to 
TGF-ß1. These examinations are on-going and will 
be presented in the near future.
Recent advances in immunomolecular studies 
have led to detailed analyses of the immunological 
effects of asbestos. Asbestos affects immunocom-
petent cells and these effects may be associated 
with the pathophysiological development of com-
plications in asbestos-exposed patients such as 
malignant tumors. In addition, immunological 
analyses may lead to the discovery of new clinical 
tools for the modiﬁ  cation of pathophysiological 
Figure 2. TcRVß expression among patients with asbestosis and malignant mesothelioma. Peripheral blood mononuclear cells (PBMCs) 
were obtained from 6 HV (mean age ± SD, 38.0 ± 6.4 years old; male(M):female(F),1:5), 9 asbestosis patients without signiﬁ  cant clinical 
signs of complications such as lung cancer or malignant mesothelioma (ASB; 74.4 ± 3.9, all males), and 12 patients with malignant meso-
thelioma (MM; 58.7 ± 10.1, M:F, 9:3). Specimens were only taken once informed consent had been obtained. The study was approved by 
the Ethics Committee of Kawasaki Medical School, Okayama Rosai Hospital, Hyogo College of Medicine and Kusaka Hospital. The expres-
sion of TcRVß in CD3+ cells derived from HV, ASB and MM subjects was examined with an IOTest Beta Mark TcRVß repertoire analysis kit 
(Beckman Coulter, Inc., Fullerton, CA) using a FACSCalibur ﬂ  ow cytometer (Becton, Dickinson and Company, Franklin Lakes, NJ) accord-
ing to the manufacturer’s instructions. This kit can analyze TcRVß 1, 2, 3, 4, 5.1, 5.2, 5.3, 7.1, 7.2, 8, 9, 11, 12, 13.1, 13.2, 13.6, 14, 16, 17, 
18, 20, 21.3, 22 and 23 from 1 ml of peripheral blood. The 0% expression in this ﬁ  gure is the mean + 2SD for HV. Thus, each symbol indicates 
the number of over-expressions observed in individual patients for individual TcRVßs.
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aspects of diseases, such as the regulation of tumor 
immunity using cell-mediated therapies, various 
cytokines and molecule-targeting therapies. As the 
incidence of asbestos-related malignancies 
increases against the growing concern in Japan 
since the summer of 2005 for medical and social 
problems created by such malignancies, efforts 
should be focused on developing a cure for these 
diseases in order to eliminate the nationwide 
anxiety concerning these malignancies.
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